Anna Schurich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anna Schurich has a total of 275 co-authors. Here are the top co-authors by number of shared publications:
- Mala K. Maini
Institute of Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK
18 shared publications - Dimitra Peppa
Division of Infection and Immunity, University College London
6 shared publications - Percy Alexander Knolle
Institute of Molecular Immunology, TUM University Hospital, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
6 shared publications - Laura J. Pallett
Institute of Infection, Immunity and Transplantation, University College London, London, UK
5 shared publications Brian R. Davidson
Division of Surgery, University College London, London, UK
4 shared publicationsDirk Stabenow
Institutes of Molecular Medicine and Experimental Immunology, University of Bonn, Bonn; and
4 shared publications
Latest Publications
- Open Access
- 26 March 2026
- Published by Elsevier in Cell Reports Methods
- Vol. 6 (4) , 101343
Single-cell assessment of iron content in primary human T cells using laser ablation inductively coupled plasma mass spectrometry
- 26 March 2026
- Published by Elsevier in Cell Reports Methods
- Vol. 6 (4) , 101343
Open AccessSingle-cell assessment of iron content in primary human T cells using laser ablation inductively coupled plasma mass spectrometry
- Open Access
- 6 January 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 220 (1)
T-cell metabolic ageing as a factor for therapeutic research
Ageing is an important determinant of immune function across the lifespan, yet it remains underappreciated in the design and interpretation of much basic T-cell research. As the immune system ages, T-cell responses become less diverse, less efficient, and less adaptable, with consequences for infection control, vaccine responsiveness, cancer immunosurveillance, and the performance of T-cell-based immunotherapies. This issue is particularly acute because many fundamental studies still rely on T cells from, mostly, healthy young donors. These controls are indispensable, but the field has built much of its pre-clinical logic on immune systems that are younger, fitter, and biologically distinct from the patients for whom T-cell therapies are intended. We argue that this mismatch between experimental systems and clinical reality could be overcome by considering age as a routine variable from the start.
- 6 January 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 220 (1)
Open AccessT-cell metabolic ageing as a factor for therapeutic research
Ageing is an important determinant of immune function across the lifespan, yet it remains underappreciated in the design and interpretation of much basic T-cell research. As the immune system ages, T-cell responses become less diverse, less efficient, and less adaptable, with consequences for infection control, vaccine responsiveness, cancer immunosurveillance, and the performance of T-cell-based immunotherapies. This issue is particularly acute because many fundamental studies still rely on T cells from, mostly, healthy young donors. These controls are indispensable, but the field has built much of its pre-clinical logic on immune systems that are younger, fitter, and biologically distinct from the patients for whom T-cell therapies are intended. We argue that this mismatch between experimental systems and clinical reality could be overcome by considering age as a routine variable from the start.
- 6 January 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 220 (1)
Fuel for thought: perspectives on immunometabolism
- 6 January 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 220 (1)
Fuel for thought: perspectives on immunometabolism
- Open Access
- 15 July 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (7) , 115973
CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients
- 15 July 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (7) , 115973
Open AccessCAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients
- Open Access
A balanced CAR-T cell metabolism driven by CD28 or 4-1BB co-stimulation correlates with clinical success in lymphoma patients
Chimeric antigen receptor (CAR) T cell therapy has led to unprecedented success in treating relapsed/refractory diffuse large B cell lymphoma (DLBCL). The most common CAR-T cell products currently in the clinic for DLBCL differ in their co-stimulation moiety, containing either CD28 or 4-1BB, which initiate distinct signalling pathways. Previous work has highlighted the importance of T cell metabolism in fuelling anti-cancer function. We have studied the metabolic characteristics induced by CD28 versus 4-1BB co-stimulation in patient CAR-T cells ex vivo . Our data show that in patients, CD28 and 4-1BB drive significantly divergent metabolic profiles. CD28 signalling endows T cells with a preferentially glycolytic metabolism supporting an effector phenotype and increased expansion capacity, while 4-1BB co-stimulation preserves mitochondrial fitness and results in memory-like differentiation. Despite this divergent programming, T cells in patients responding successfully to therapy were metabolically similar, irrespective of co-stimulator, suggesting that efficient fuelling of CAR-T cells in lymphoma requires a ‘ balanced’ metabolism. In contrast, CAR-T cells in non-responders were pushed to their metabolic extremes. One sentence summary: CD28 and 4-1BB signalling drive divergent metabolic profiles in patient CAR-T cells, however patients that respond to therapy have CAR-T cells that maintain metabolic balance.
Open AccessA balanced CAR-T cell metabolism driven by CD28 or 4-1BB co-stimulation correlates with clinical success in lymphoma patients
Chimeric antigen receptor (CAR) T cell therapy has led to unprecedented success in treating relapsed/refractory diffuse large B cell lymphoma (DLBCL). The most common CAR-T cell products currently in the clinic for DLBCL differ in their co-stimulation moiety, containing either CD28 or 4-1BB, which initiate distinct signalling pathways. Previous work has highlighted the importance of T cell metabolism in fuelling anti-cancer function. We have studied the metabolic characteristics induced by CD28 versus 4-1BB co-stimulation in patient CAR-T cells ex vivo . Our data show that in patients, CD28 and 4-1BB drive significantly divergent metabolic profiles. CD28 signalling endows T cells with a preferentially glycolytic metabolism supporting an effector phenotype and increased expansion capacity, while 4-1BB co-stimulation preserves mitochondrial fitness and results in memory-like differentiation. Despite this divergent programming, T cells in patients responding successfully to therapy were metabolically similar, irrespective of co-stimulator, suggesting that efficient fuelling of CAR-T cells in lymphoma requires a ‘ balanced’ metabolism. In contrast, CAR-T cells in non-responders were pushed to their metabolic extremes. One sentence summary: CD28 and 4-1BB signalling drive divergent metabolic profiles in patient CAR-T cells, however patients that respond to therapy have CAR-T cells that maintain metabolic balance.
- Open Access
- 22 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (4)
IL-15 reprogramming compensates for NK cell mitochondrial dysfunction in HIV-1 infection
Dynamic regulation of cellular metabolism is important for maintaining homeostasis and can directly influence immune cell function and differentiation, including NK cell responses. Persistent HIV-1 infection leads to a state of chronic immune activation, NK cell subset redistribution, and progressive NK cell dysregulation. In this study, we examined the metabolic processes that characterize NK cell subsets in HIV-1 infection, including adaptive NK cell subpopulations expressing the activating receptor NKG2C, which expand during chronic infection. These adaptive NK cells exhibit an enhanced metabolic profile in HIV-1 – individuals infected with human cytomegalovirus (HCMV). However, the bioenergetic advantage of adaptive CD57 + NKG2C + NK cells is diminished during chronic HIV-1 infection, where NK cells uniformly display reduced oxidative phosphorylation (OXPHOS). Defective OXPHOS was accompanied by increased mitochondrial depolarization, structural alterations, and increased DRP-1 levels promoting fission, suggesting that mitochondrial defects are restricting the metabolic plasticity of NK cell subsets in HIV-1 infection. The metabolic requirement for the NK cell response to receptor stimulation was alleviated upon IL-15 pretreatment, which enhanced mammalian target of rapamycin complex 1 (mTORC1) activity. IL-15 priming enhanced NK cell functionality to anti-CD16 stimulation in HIV-1 infection, representing an effective strategy for pharmacologically boosting NK cell responses.
- 22 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (4)
Open AccessIL-15 reprogramming compensates for NK cell mitochondrial dysfunction in HIV-1 infection
Dynamic regulation of cellular metabolism is important for maintaining homeostasis and can directly influence immune cell function and differentiation, including NK cell responses. Persistent HIV-1 infection leads to a state of chronic immune activation, NK cell subset redistribution, and progressive NK cell dysregulation. In this study, we examined the metabolic processes that characterize NK cell subsets in HIV-1 infection, including adaptive NK cell subpopulations expressing the activating receptor NKG2C, which expand during chronic infection. These adaptive NK cells exhibit an enhanced metabolic profile in HIV-1 – individuals infected with human cytomegalovirus (HCMV). However, the bioenergetic advantage of adaptive CD57 + NKG2C + NK cells is diminished during chronic HIV-1 infection, where NK cells uniformly display reduced oxidative phosphorylation (OXPHOS). Defective OXPHOS was accompanied by increased mitochondrial depolarization, structural alterations, and increased DRP-1 levels promoting fission, suggesting that mitochondrial defects are restricting the metabolic plasticity of NK cell subsets in HIV-1 infection. The metabolic requirement for the NK cell response to receptor stimulation was alleviated upon IL-15 pretreatment, which enhanced mammalian target of rapamycin complex 1 (mTORC1) activity. IL-15 priming enhanced NK cell functionality to anti-CD16 stimulation in HIV-1 infection, representing an effective strategy for pharmacologically boosting NK cell responses.
- Open Access
Extracellular vesicles in COVID-19 convalescence can regulate T cell metabolism and function
- 25 January 2023
- Published by Springer Nature in Nature
- Vol. 614 (7947) , 334-342
Tissue CD14+CD8+ T cells reprogrammed by myeloid cells and modulated by LPS
The liver is bathed in bacterial products, including lipopolysaccharide transported from the intestinal portal vasculature, but maintains a state of tolerance that is exploited by persistent pathogens and tumours1,2,3,4. The cellular basis mediating this tolerance, yet allowing a switch to immunity or immunopathology, needs to be better understood for successful immunotherapy of liver diseases. Here we show that a variable proportion of CD8+ T cells compartmentalized in the human liver co-stain for CD14 and other prototypic myeloid membrane proteins and are enriched in close proximity to CD14high myeloid cells in hepatic zone 2. CD14+CD8+ T cells preferentially accumulate within the donor pool in liver allografts, among hepatic virus-specific and tumour-infiltrating responses, and in cirrhotic ascites. CD14+CD8+ T cells exhibit increased turnover, activation and constitutive immunomodulatory features with high homeostatic IL-10 and IL-2 production ex vivo, and enhanced antiviral/anti-tumour effector function after TCR engagement. This CD14+CD8+ T cell profile can be recapitulated by the acquisition of membrane proteins—including the lipopolysaccharide receptor complex—from mononuclear phagocytes, resulting in augmented tumour killing by TCR-redirected T cells in vitro. CD14+CD8+ T cells express integrins and chemokine receptors that favour interactions with the local stroma, which can promote their induction through CXCL12. Lipopolysaccharide can also increase the frequency of CD14+CD8+ T cells in vitro and in vivo, and skew their function towards the production of chemotactic and regenerative cytokines. Thus, bacterial products in the gut–liver axis and tissue stromal factors can tune liver immunity by driving myeloid instruction of CD8+ T cells with immunomodulatory ability.
- 25 January 2023
- Published by Springer Nature in Nature
- Vol. 614 (7947) , 334-342
Tissue CD14+CD8+ T cells reprogrammed by myeloid cells and modulated by LPS
The liver is bathed in bacterial products, including lipopolysaccharide transported from the intestinal portal vasculature, but maintains a state of tolerance that is exploited by persistent pathogens and tumours1,2,3,4. The cellular basis mediating this tolerance, yet allowing a switch to immunity or immunopathology, needs to be better understood for successful immunotherapy of liver diseases. Here we show that a variable proportion of CD8+ T cells compartmentalized in the human liver co-stain for CD14 and other prototypic myeloid membrane proteins and are enriched in close proximity to CD14high myeloid cells in hepatic zone 2. CD14+CD8+ T cells preferentially accumulate within the donor pool in liver allografts, among hepatic virus-specific and tumour-infiltrating responses, and in cirrhotic ascites. CD14+CD8+ T cells exhibit increased turnover, activation and constitutive immunomodulatory features with high homeostatic IL-10 and IL-2 production ex vivo, and enhanced antiviral/anti-tumour effector function after TCR engagement. This CD14+CD8+ T cell profile can be recapitulated by the acquisition of membrane proteins—including the lipopolysaccharide receptor complex—from mononuclear phagocytes, resulting in augmented tumour killing by TCR-redirected T cells in vitro. CD14+CD8+ T cells express integrins and chemokine receptors that favour interactions with the local stroma, which can promote their induction through CXCL12. Lipopolysaccharide can also increase the frequency of CD14+CD8+ T cells in vitro and in vivo, and skew their function towards the production of chemotactic and regenerative cytokines. Thus, bacterial products in the gut–liver axis and tissue stromal factors can tune liver immunity by driving myeloid instruction of CD8+ T cells with immunomodulatory ability.
- 13 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (640) , eabi4670
NK cells limit therapeutic vaccine–induced CD8 + T cell immunity in a PD-L1–dependent manner
A better understanding of mechanisms that regulate CD8 + T cell responses to therapeutic vaccines is needed to develop approaches to enhance vaccine efficacy for chronic viral infections and cancers. We show here that NK cell depletion enhanced antigen-specific T cell responses to chimp adenoviral vector (ChAdOx) vaccination in a mouse model of chronic HBV infection (CHB). Probing the mechanism underlying this negative regulation, we observed that CHB drove parallel up-regulation of programmed cell death ligand 1 (PD-L1) on liver-resident NK cells and programmed cell death 1 (PD-1) on intrahepatic T cells. PD-L1–expressing liver-resident NK cells suppressed PD-1 hi CD8 + T cells enriched within the HBV-specific response to therapeutic vaccination. Cytokine activation of NK cells also induced PD-L1, and combining cytokine activation with PD-L1 blockade resulted in conversion of NK cells into efficient helpers that boosted HBV-specific CD8 + T cell responses to therapeutic vaccination in mice and to chronic infection in humans. Our findings delineate an immunotherapeutic combination that can boost the response to therapeutic vaccination in CHB and highlight the broader importance of PD-L1–dependent regulation of T cells by cytokine-activated NK cells.
- 13 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (640) , eabi4670
NK cells limit therapeutic vaccine–induced CD8 + T cell immunity in a PD-L1–dependent manner
A better understanding of mechanisms that regulate CD8 + T cell responses to therapeutic vaccines is needed to develop approaches to enhance vaccine efficacy for chronic viral infections and cancers. We show here that NK cell depletion enhanced antigen-specific T cell responses to chimp adenoviral vector (ChAdOx) vaccination in a mouse model of chronic HBV infection (CHB). Probing the mechanism underlying this negative regulation, we observed that CHB drove parallel up-regulation of programmed cell death ligand 1 (PD-L1) on liver-resident NK cells and programmed cell death 1 (PD-1) on intrahepatic T cells. PD-L1–expressing liver-resident NK cells suppressed PD-1 hi CD8 + T cells enriched within the HBV-specific response to therapeutic vaccination. Cytokine activation of NK cells also induced PD-L1, and combining cytokine activation with PD-L1 blockade resulted in conversion of NK cells into efficient helpers that boosted HBV-specific CD8 + T cell responses to therapeutic vaccination in mice and to chronic infection in humans. Our findings delineate an immunotherapeutic combination that can boost the response to therapeutic vaccination in CHB and highlight the broader importance of PD-L1–dependent regulation of T cells by cytokine-activated NK cells.
- Open Access
- 21 December 2021
- Published by Elsevier in Cell Reports Medicine
- Vol. 2 (12) , 100457
Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors
- 21 December 2021
- Published by Elsevier in Cell Reports Medicine
- Vol. 2 (12) , 100457
Open AccessSynergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors